B Cells Linked to Immunotherapy Colitis Risk
Researchers have identified B cell levels as a potential predictor for intestinal inflammation during cancer treatment.
Updated on Sept. 22, 2026 in Cancer
Live Poll
Does understanding treatment side effects in advance make you feel more confident about receiving new therapies?
A new study has identified B cells as a primary driver of colitis in patients receiving immune checkpoint inhibitor therapy. These findings suggest that monitoring B cell levels could help clinicians identify patients at higher risk for this side effect before treatment begins.
Why it matters
Identifying early indicators of colitis is critical for managing the long-term health and treatment consistency of cancer patients. This research potentially opens new avenues for preventive care by targeting B cells or addressing gut microbiome health.
Published in Cell Reports, this preclinical and patient-sample study demonstrates that B cells drive immune-related colitis. Researchers found that B cell activation precedes the expansion of inflammatory T cells, establishing a cascade of tissue damage.
The players
University of Texas MD Anderson Cancer Center
A premier institution focused on cancer care, research, and the development of innovative immunotherapies.
Cleveland Clinic
A globally recognized academic medical center specializing in complex patient care and clinical research.
The details
The study suggests that B cell dysregulation initiates an inflammatory cascade that leads to tissue damage in the colon. Researchers observed that depleting B cells in preclinical models effectively reduced both intestinal damage and subsequent T cell inflammatory responses. Furthermore, the findings indicate that gut microbiome composition plays a role in susceptibility, as fecal microbiota transplantation reduced the severity of colitis in these models.
Timeline
The study was published on September 22, 2026.
Health Landscape
This work advances the standard of care for patients on immune checkpoint inhibitors by shifting the focus toward pre-treatment biomarkers. It sits within the growing field of immuno-oncology research aimed at decoupling therapeutic success from debilitating autoimmune side effects.
If you are preparing for immunotherapy, it is worth discussing with your doctor whether your clinical team monitors for signs of immune-related side effects. Ask your physician about known risk factors and whether you should report specific digestive symptoms early during your treatment course.
The takeaway
This study highlights the importance of B cell activity in predicting therapy-related colitis, offering a potential path to better preventive screenings. Patients receiving immunotherapy should maintain open communication with their oncology team regarding any changes in bowel habits.
Further reading
For more information on the latest developments in managing treatment-related side effects, visit our section on Cancer.
More information
You can read the full findings in the peer-reviewed research article01047-8).
Source note: This article includes information reported by News-Medical.
Live Poll
Does understanding treatment side effects in advance make you feel more confident about receiving new therapies?
